{"url_path":"/sec/rnxt/10-q/2026/item-6","section_key":"item-6","section_title":"Item 6 Exhibits","topic":"sec","document":{"doc_type":"10-Q","doc_date":"2026-05-14","source_url":"https://www.sec.gov/Archives/edgar/data/1574094/0001193125-26-224100-index.html","accession_number":"0001193125-26-224100","cik":"0001574094","ticker":"RNXT","issuer_name":"RenovoRx, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1574094/0001193125-26-224100-index.html","primary_entity_key":"0001574094","primary_entity_name":"RenovoRx, Inc."},"word_count":749,"has_tables":true,"body_markdown":"Item 6. Exhibits\n\n \n\nIncorporated by Reference\n\nExhibit Number\n\nExhibit Description\n\nForm\n\nFile No.\n\nExhibit\n\nFiling Date\n\n3.1\n\n[Sixth Amended and Restated Certificate of Incorporation of RenovoRx, Inc.](https://www.sec.gov/Archives/edgar/data/1574094/000149315221021705/ex3-1.htm)\n\n8-K\n\n001-40738\n\n3.1\n\nAugust 31, 2021\n\n3.2\n\n[Amended and Restated Bylaws of RenovoRx, Inc.](https://www.sec.gov/Archives/edgar/data/1574094/000149315223032160/ex3-1.htm)\n\n8-K\n\n001-40738\n\n3.1\n\nSeptember 11, 2023\n\n4.1\n\n[Form of Private Common Stock Warrant (related to the 2020 Convertible Notes and 2021 Convertible Notes)](https://www.sec.gov/Archives/edgar/data/1574094/000149315221028585/ex4-1.htm)\n\n10-Q\n\n001-40738\n\n4.1\n\nNovember 15, 2021\n\n4.2\n\n[Form of Underwriter’s Warrant](https://www.sec.gov/Archives/edgar/data/1574094/000149315221018772/ex4-1.htm)\n\nS-1\n\n333-258071\n\n4.1\n\nAugust 25, 2021\n\n4.3\n\n[Form of Warrant Agent Agreement (including the terms of the Warrants)](https://www.sec.gov/Archives/edgar/data/1574094/000149315221019398/ex4-2.htm)\n\nS-1\n\n333-258071\n\n4.2\n\nAugust 25, 2021\n\n4.4\n\n[Specimen Stock Certificate evidencing the Shares of Common Stock](https://www.sec.gov/Archives/edgar/data/1574094/000149315221018772/ex4-4.htm)\n\nS-1\n\n333-258071\n\n4.4\n\nAugust 25, 2021\n\n4.5\n\n[Form of Warrant Certificate](https://www.sec.gov/Archives/edgar/data/1574094/000149315221018772/ex4-5.htm)\n\nS-1\n\n333-258071\n\n4.5\n\nAugust 25, 2021\n\n4.6\n\n[Form of Pre-Funded Common Stock Purchase Warrant](https://www.sec.gov/Archives/edgar/data/1574094/000149315223010652/ex4-1.htm)\n\n8-K\n\n001-40738\n\n4.1\n\nApril 3, 2023\n\n4.7\n\n[Form of Common Stock Purchase Warrant](https://www.sec.gov/Archives/edgar/data/1574094/000149315223010652/ex4-2.htm)\n\n8-K\n\n001-40738\n\n4.2\n\nApril 3, 2023\n\n4.8\n\n[Warrant to Purchase Common Stock of RenovoRx, Inc.](https://www.sec.gov/Archives/edgar/data/1574094/000149315224004083/ex10-3.htm)\n\n8-K\n\n001-40738\n\n10.3\n\nJanuary 29, 2024\n\n4.9\n\n[RenovoRx Placement Agent Warrant](https://www.sec.gov/Archives/edgar/data/1574094/000149315224004083/ex10-5.htm)\n\n8-K\n\n001-40738\n\n10.5\n\nJanuary 29, 2024\n\n4.10\n\n[Form of Pre-Funded Common Stock Purchase Warrant of RenovoRx, Inc.](https://www.sec.gov/Archives/edgar/data/1574094/000149315224014559/ex10-2.htm)\n\n8-K\n\n001-40738\n\n10.2\n\nApril 15, 2024\n\n4.11\n\n[Form of Series A Warrant to Purchase Common Stock of RenovoRx, Inc.](https://www.sec.gov/Archives/edgar/data/1574094/000149315224014559/ex10-3.htm)\n\n8-K\n\n001-40738\n\n10.3\n\nApril 15, 2024\n\n4.12\n\n[Form of Series B Warrant to Purchase Common Stock of RenovoRx, Inc.](https://www.sec.gov/Archives/edgar/data/1574094/000149315224014559/ex10-4.htm)\n\n8-K\n\n001-40738\n\n10.4\n\nApril 15, 2024\n\n4.13\n\n[Form of Placement Agent Warrant to Purchase Common Stock of RenovoRx, Inc.](https://www.sec.gov/Archives/edgar/data/1574094/000149315224014559/ex10-5.htm)\n\n8-K\n\n001-40738\n\n10.5\n\nApril 15, 2024\n\n4.14\n\n[Common Stock Purchase Warrant Issued to Medical Murray, Inc., dated September 25, 2024](https://www.sec.gov/Archives/edgar/data/1574094/000149315224045137/ex4-14.htm)\n\n10-Q\n\n001-40738\n\n4.14\n\nNovember 13, 2024\n\n4.15\n\n[Form of Underwriter Warrant issued in February 2025 Public Offering](https://www.sec.gov/Archives/edgar/data/1574094/000149315225005559/ex4-1.htm)\n\n8-K\n\n001-40738\n\n4.1\n\nFebruary 10, 2025\n\n4.16\n\n \n\n[Form of Pre-Funded Warrant Issued to Investors in the March 2026 Private Placement](https://www.sec.gov/Archives/edgar/data/1574094/000149315226012058/ex4-1.htm)\n\n \n\n8-K\n\n \n\n001-40738\n\n \n\n4.1\n\n \n\nMarch 23, 2026\n\n4.17\n\n \n\n[Form of Milestone Warrant Issued to Investors in the March 2026 Private Placement](https://www.sec.gov/Archives/edgar/data/1574094/000149315226012058/ex4-2.htm)\n\n \n\n8-K\n\n \n\n001-40738\n\n \n\n4.2\n\n \n\nMarch 23, 2026\n\n10.1+#\n\n \n\n[Consulting Agreement, dated February 4, 2026, by and between the Company and Mark Voll](https://www.sec.gov/Archives/edgar/data/1574094/000149315226005437/ex10-1.htm)\n\n \n\n8-K\n\n \n\n001-40738\n\n \n\n10.1\n\n \n\nFebruary 6, 2026\n\n10.2\n\n \n\n[Form of Securities Purchase Agreement in the March 2026 Private Placement](https://www.sec.gov/Archives/edgar/data/1574094/000149315226012058/ex10-1.htm)\n\n \n\n8-K\n\n \n\n001-40738\n\n \n\n10.1\n\n \n\nMarch 23, 2026\n\n10.3+\n\n \n\n[Agah Offer Letter, dated March 24, 2026 and effective February 27, 2026, by and between the Company and Ramtin Agah](https://www.sec.gov/Archives/edgar/data/1574094/000149315226013080/ex10-1.htm)\n\n \n\n8-K\n\n \n\n001-40738\n\n \n\n10.1\n\n \n\nMarch 27, 2026\n\n31.1\n\n[Certification of Principal Executive Officer pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.](rnxt-ex31_1.htm)\n\nFiled herewith\n\n31.2\n\n[Certification of Principal Financial Officer pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted](rnxt-ex31_2.htm)\n\nFiled herewith\n\n36\n\n \n\n \n\n \n\nPursuant to Section 302 of the Sarbanes-Oxley Act of 2002.\n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n32.1†\n\n[Certification of Principal Executive Officer pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.](rnxt-ex32_1.htm)\n\nFurnished herewith\n\n32.2†\n\n[Certification of Principal Financial Officer pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.](rnxt-ex32_2.htm)\n\nFurnished herewith\n\n101.INS\n\nInline XBRL Instance Document-the instance document does not appear in the Interactive Data File as its XBRL tags are embedded within the Inline XBRL document\n\nFiled herewith\n\n101.SCH\n\nInline XBRL Taxonomy Extension Schema with Embedded Linkbase Documents\n\nFiled herewith\n\n104\n\nCover Page formatted as Inline XBRL and contained in Exhibit 101\n\nFiled herewith\n\n \n\n† The certifications attached as Exhibits 32.1 and 32.2 that accompany this Quarterly Report on Form 10-Q are deemed furnished and not filed with the Securities and Exchange Commission and are not to be incorporated by reference into any filing of the Registrant under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, whether made before or after the date of this Quarterly Report on Form 10-Q, irrespective of any general incorporation language contained in such filing.\n\n+ Certain information has been omitted from this exhibit pursuant to Item 601(a)(6) or Item 601(b)(10)(iv) of Regulation S-K.\n\n# Indicates management contract or compensatory plan or arrangement.\n\n \n\n37\n\n \n\nSIGNATURES\n\nPursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.\n\n \n\n \n\nRenovoRx, Inc.\n\n \n\n \n\n \n\nDate: May 14, 2026\n\nBy:\n\n/s/ Shaun R. Bagai\n\n \n\n \n\nShaun R. Bagai\n\n \n\n \n\nChief Executive Officer\n\n \n\n \n\n(Principal Executive Officer)\n\n \n\n \n\n \n\nDate: May 14, 2026\n\nBy:\n\n/s/ Mark Voll\n\n \n\n \n\nMark Voll\n\n \n\n \n\nChief Financial Officer\n\n \n\n \n\n(Principal Financial Officer)\n\n \n\n38"}